Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Illuminare-1 is a single dose injectable myelin binding fluorescent agent currently in development to provide real time visualization and delineation of nerves potentially as small as ~60 micron during both open and minimally invasive surgery under blue ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : Illuminare-1
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Fluorescent Imaging of Nerves with Illuminare-1 During Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2021
Lead Product(s) : Illuminare-1
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable